|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM192A |
Gene summary for FAM192A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM192A | Gene ID | 80011 |
| Gene name | proteasome activator subunit 3 interacting protein 1 | |
| Gene Alias | C16orf94 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A024R6T8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80011 | FAM192A | LZE2T | Human | Esophagus | ESCC | 1.36e-04 | 8.27e-01 | 0.082 |
| 80011 | FAM192A | LZE4T | Human | Esophagus | ESCC | 6.56e-17 | 5.34e-01 | 0.0811 |
| 80011 | FAM192A | LZE7T | Human | Esophagus | ESCC | 5.16e-10 | 5.81e-01 | 0.0667 |
| 80011 | FAM192A | LZE8T | Human | Esophagus | ESCC | 1.19e-09 | 4.05e-01 | 0.067 |
| 80011 | FAM192A | LZE20T | Human | Esophagus | ESCC | 4.11e-04 | 2.56e-01 | 0.0662 |
| 80011 | FAM192A | LZE22T | Human | Esophagus | ESCC | 3.70e-02 | 3.49e-01 | 0.068 |
| 80011 | FAM192A | LZE24T | Human | Esophagus | ESCC | 2.14e-25 | 6.76e-01 | 0.0596 |
| 80011 | FAM192A | LZE21T | Human | Esophagus | ESCC | 3.69e-04 | 4.43e-01 | 0.0655 |
| 80011 | FAM192A | LZE6T | Human | Esophagus | ESCC | 3.51e-04 | 2.30e-01 | 0.0845 |
| 80011 | FAM192A | P1T-E | Human | Esophagus | ESCC | 1.55e-13 | 6.31e-01 | 0.0875 |
| 80011 | FAM192A | P2T-E | Human | Esophagus | ESCC | 4.77e-23 | 4.75e-01 | 0.1177 |
| 80011 | FAM192A | P4T-E | Human | Esophagus | ESCC | 4.50e-43 | 9.27e-01 | 0.1323 |
| 80011 | FAM192A | P5T-E | Human | Esophagus | ESCC | 8.86e-30 | 5.72e-01 | 0.1327 |
| 80011 | FAM192A | P8T-E | Human | Esophagus | ESCC | 3.49e-41 | 7.80e-01 | 0.0889 |
| 80011 | FAM192A | P9T-E | Human | Esophagus | ESCC | 1.38e-15 | 3.86e-01 | 0.1131 |
| 80011 | FAM192A | P10T-E | Human | Esophagus | ESCC | 1.49e-22 | 3.30e-01 | 0.116 |
| 80011 | FAM192A | P11T-E | Human | Esophagus | ESCC | 2.84e-20 | 7.22e-01 | 0.1426 |
| 80011 | FAM192A | P12T-E | Human | Esophagus | ESCC | 2.58e-18 | 3.82e-01 | 0.1122 |
| 80011 | FAM192A | P15T-E | Human | Esophagus | ESCC | 8.35e-31 | 5.88e-01 | 0.1149 |
| 80011 | FAM192A | P16T-E | Human | Esophagus | ESCC | 6.40e-19 | 3.31e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM192A | SNV | Missense_Mutation | c.593N>T | p.Pro198Leu | p.P198L | Q9GZU8 | protein_coding | deleterious(0.02) | benign(0) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| FAM192A | insertion | Nonsense_Mutation | novel | c.602_603insGGACATCAAAGTCATCATCTTTATGTGGCATGACTCTTAAGAGG | p.His201GlnfsTer14 | p.H201Qfs*14 | Q9GZU8 | protein_coding | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| FAM192A | SNV | Missense_Mutation | c.637C>T | p.Pro213Ser | p.P213S | Q9GZU8 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM192A | SNV | Missense_Mutation | c.311N>A | p.Arg104Gln | p.R104Q | Q9GZU8 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FAM192A | SNV | Missense_Mutation | c.667G>A | p.Asp223Asn | p.D223N | Q9GZU8 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FAM192A | SNV | Missense_Mutation | c.311N>A | p.Arg104Gln | p.R104Q | Q9GZU8 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM192A | SNV | Missense_Mutation | novel | c.110N>C | p.Lys37Thr | p.K37T | Q9GZU8 | protein_coding | tolerated(0.42) | possibly_damaging(0.634) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM192A | SNV | Missense_Mutation | novel | c.374N>A | p.Ser125Tyr | p.S125Y | Q9GZU8 | protein_coding | deleterious(0.03) | benign(0.084) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| FAM192A | SNV | Missense_Mutation | c.311N>A | p.Arg104Gln | p.R104Q | Q9GZU8 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| FAM192A | SNV | Missense_Mutation | rs535488737 | c.70N>T | p.Arg24Trp | p.R24W | Q9GZU8 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |